Elevation of total PSA after intravesical BCG instillations: Granulomatous prostatitis or prostatic adenocarcinoma?;Élévation du PSA total après instillations endovesicales de BCG : prostatite granulomateuse ou adénocarcinome prostatique ?

Progres en Urologie

Volumn 18, Issue 2, 2008, Pages 108-113

  Blah, M ^a   Gobet, F ^a   Dugardin, F ^a   Catovic, B ^a   Loisel, F ^a   Pfister, C ^a  

^a HÔPITAL CHARLES NICOLLE   (France)

Author keywords

BCG; Granulomatous prostatitis; Intravesical instillations; Prostate specific antigen; Superficial bladder cancer

Indexed keywords

BCG VACCINE; PROSTATE SPECIFIC ANTIGEN;

ADENOMA; ARTICLE; BLADDER TUMOR; BLOOD; DIFFERENTIAL DIAGNOSIS; DRUG ADMINISTRATION; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; MALE; PROSTATE TUMOR; PROSTATITIS; RETROSPECTIVE STUDY;

ADENOMA; ADMINISTRATION, INTRAVESICAL; BCG VACCINE; DIAGNOSIS, DIFFERENTIAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROSTATITIS; RETROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS;

EID: 56349098308     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.purol.2007.12.007     Document Type: Article

References (27)

1. Gattegno B., and Chopin D. Rapport 2001 de l'Association Française d'Urologie. Prog Urol 11 (2001) 993-1019
2. Irani J., Bernardini S., Bonnal J.L., et al. Tumeurs urothéliales. Prog Urol 14 (2004) 957-996
3. Saint F., Irani J., Salomon L., Debois H., Abbou C.C., and Chopin D. Étude de la tolérance et de l'efficacité des instillations endovésicales de Bacille Calmette-Guérin dans le traitement prophylactique des tumeurs superficielles de vessie, en utilisant un traitement d'entretien. Prog Urol 11 (2001) 647-656
4. Lamm D.L., Blumenstein B.A., and Crissman J.D. Maintenance Bacillus Calmette-Guérin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol 163 (2000) 1124-1129
5. Aust T.R., and Massey J.A. Tubercular prostatic abcess as a complication of intravesical BCG immunotherapy. Int J Urol 12 (2005) 920-921
6. Falkensammer C., Gozzi C., Hager M., et al. Late occurrence of bilateral tuberculous-like epididymo-orchitis after intravesical BCG therapy for superficial bladder carcinoma. Urology 65 (2005) 175
7. Epstein J.I., and Hutchins G.M. Granulomatous prostatitis: distinction among allergic, nonspecific and post-transurethral resection lesions. Hum Pathol 15 (1984) 818-825
8. Uzoh C.C., Uff J.S., and Okeke A.A. Granulomatous prostatitis. BJU Int 12 (2006) 1-3
9. Garcia-Solano J., Sanchez-Sanchez C., Montalban-Romero S., and Perez-Gillermo M. Diagnostic dilemmas in the interpretation of fine-needle aspirates of granulomatous prostatitis. Diagn Cytopathol 18 (1998) 215-221
10. Mukamel E., Konichezky M., Engelstein D., et al. Clinical and pathological findings in prostates after following intravesical Bacillus Calmette-Guérin instillations. J Urol 144 (1990) 1399
11. Leibovici D., Zisman A., Chen-Levyi Z., Cypele H., et al. Elevated prostate specific antigen serum level after intravesical instillation of Bacillus Calmette-Guérin. J Urol 164 (2000) 1546-1549
12. Lamm D.L., Stogdill V.D., Stogdill B.J., and Crispen R.G. Complications of Bacillus Calmette-Guérin immunotherapy in 1278 patients with bladder cancer. J Urol 135 (1986) 272-274
13. Rischmann P., Desgrandchamps F., Malavaud B., and Chopin D.K. BCG intravesical instillations: recommendations for side-effects management. Eur Urol 37 Suppl. 1 (2007) 33-36
14. Palou J., Lopez H., Millan F., Oliver A., Salvator J., and Vincente-Rodriguez J. Effect of intravesical instillations of BCG on total PSA. Preliminary results. BJU Int 86 (2000) 254
15. Bassi P.F., Spinadin R., Carando R., Balta G., and Pagano F. Modified induction course: a solution to side effects?. Eur Urol 37 Suppl. 1 (2000) 31-32
16. Colombel M., Saint F., Chopin D., Malavaud B., Nicolas L., and Rischman P. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol 176 (2006) 935-939
17. Losa A., Hurle R., and Lembo A. Low dose Bacillus Calmette-Guérin for carcinoma in situ of the bladder: long term results. J Urol 163 (2000) 68-72
18. Mack D., Höltl W., Bassi P., et al. The ablative effect of quarter dose Bacillus Calmette Guerin on a papillary marker lesion of the bladder. J Urol 165 (2001) 401-403
19. Palou J., Laguna P., Millan-Rodriguez F., et al. Control group and maintenance treatment with Bacillus Calmette-Guérin for carcinoma in situ and/or high grade bladder tumors. J Urol 165 (2001) 1488-1491
20. Cookson M.S., Herr H.W., Zhang Z.F., Soloway S., Sogani P., and Fair W. The treated natural history of high-risk superficial bladder cancer: 15-year outcome. J Urol 158 (1997) 62-67
21. Cummings K.B., Barone J.G., and Ward W.S. Diagnosis and staging of bladder cancer. Urol Clin North Am 19 (1992) 455-465
22. Droller M.J. Markers in bladder cancer - issues to consider. J Urol 160 (1998) 2009-2010
23. De Reijke T.M., De Boer E.C., Kurth K.H., and Schamhart D.H.J. Urinary interleukin-2 monitoring during prolonged BCG treatment: can it predict the optimal number of instillations?. J Urol 161 (1999) 67-71
24. Rabinowitz R., Smith D.S., Tiemann D.D., and Hudson M. Urinary interleukin-8/creatinine level as predictor of response to intravesical BCG therapy in bladder tumor patients. J Urol 158 (1997) 1728-1732
25. Thalmann G.N., Dewald B., Baggliolini M., and Studer U.E. Interleukin-8 expression in the urine after BCG therapy: a potential prognostic factor of tumor recurrence and progression. J Urol 158 (1997) 1340-1344
26. Datta S.N., Allen G.M., Evans R., Vaughton K.C., and Lucas M.G. Urinary tract ultrasonography in the evaluation of haematuria - a revue over 1,000 cases. Ann R Coll Surg Engl 84 (2002) 203-205
27. Martinez-Pineiro J.A., Martinez-Pineiro L., Solsona E., et al. Has a 3-fold decreased dose of BCG the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 174 (2005) 1242-1247